๐Ÿ‡ฎ๐Ÿ‡ชIreland
16ยฐC Partly Cloudy ยท Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Norwich
Clinical trial register · United Kingdom · industry-sponsored

Clinical Trials in Norwich, 2026

Every industry-sponsored study on the ClinicalTrials.gov registry that lists a UK site and is open, about to open, active-but-closed, or enrolling by invitation. This deliberately excludes academic and other non-industry sponsors โ€” the full UK registry across all sponsors is far larger. UK studies may also be registered separately on ISRCTN.

Download CSV
Source: ClinicalTrials.gov. Complete coverage of the industry-sponsored slice โ€” all 2853 matching records are in this view (non-industry sponsors are out of scope by design, not truncated). Synced 25 Sep 2026, 03:15 UTC
2853
Studies in scope
industry-sponsored, all four open statuses
1387
Recruiting now
open to new participants
544
Lead sponsors
across recruiting studies
Top sites
London 2012 Manchester 669 Birmingham 470 Glasgow 439 Cambridge 418
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
AstraZeneca7 AbbVie4 BeOne Medicines4 Sanofi3 Janssen Research & Development, LLC3
Site city
London2012 Manchester669 Birmingham470 Glasgow439 Cambridge418
All 425 cities
Target enrolment
to

Trials with a site in Norwich

57 of 2853 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
UK sites
Start
Recruiting
A Study to Investigate Safety, Reactogenicity, and Immunogenicity of mRNA-1365 (Profile 2) in Older Healthy Adults
NCT07764237Respiratory Syncytial Virus (RSV), Human Metapneuomovirus (hMPV)
DrugsMRNA-1345·MRNA-1365
ModernaTX, Inc.
Phase 1
375
Manchester, Southampton, Norwich, Birmingham, London, Newcastle
2026-08-11
Recruiting
A Research Study to Look at How Well NNC0487-0111 Works Compared to Placebo in People With Heart Failure and Obesity
NCT07567001Obesity, Heart Failure
DrugNNC0487-0111
Novo Nordisk A/S
Phase 3
5,610
Truro, Rhyl, Torquay, Dorchester, Airdrie, Tooting, Isleworth, Norwich
2026-05-11
Recruiting
UK PureWickโ„ข At-Home Pilot Study
NCT07555548Urinary Incontinence
Becton, Dickinson and Company
Observational
95
Doncaster, Leicester, Northampton, Norwich
2026-05-06
Recruiting
A Study of Guselkumab Versus Risankizumab in Participants With Moderately to Severely Active Crohn's Disease
NCT07499232Crohn Disease
DrugsRisankizumab·Guselkumab
Janssen Research & Development, LLC
Phase 3
530
Greater London, Iselworth, London, Norwich, Wolverhampton
2026-04-21
Recruiting
A Study to Evaluate Chemotherapy With or Without INCB161734 in Previously Untreated, KRAS G12D-Mutated Metastatic Pancreatic Ductal Adenocarcinoma
NCT07522073Solid Tumors
DrugINCB161734
Incyte Corporation
Phase 3
588
Dundee, Guildford, Headington, Leeds, London, Manchester, Northwood, Norwich
2026-04-09
Recruiting
A Study to Evaluate the Efficacy of Pumitamig Versus Pembrolizumab in Participants With Previously Untreated Advanced Non-Small Cell Lung Cancer and PD-L1 โ‰ฅ 50%. (ROSETTA Lung-202)
NCT07361510Non-Small Cell Lung Cancer (NSCLC)
DrugsPumitamig·Pembrolizumab
Bristol-Myers Squibb
Phase 3
750
Aberdeen, Middlesbrough, Norwich, Sutton, Cambridge, Cardiff, Guildford, London
2026-03-12
Recruiting
Evaluation of PLG0206 in Prevention of Recurrent Infection in Patients Undergoing Debridement, Antibiotics, and Implant Retention (DAIR) for Treatment of a Periprosthetic Joint Infection (PJI) Following Knee Arthroplasty
NCT07214311Prosthetic-joint Infection
Peptilogics
Phase 2/3
240
Cambridge, Edinburgh, Norwich, Leeds
2026-02-03
Recruiting
Study of ABBV-142 to Assess Adverse Events and Change in Disease Activity in Adult Participants With Idiopathic Pulmonary Fibrosis
NCT07230288Idiopathic Pulmonary Fibrosis
AbbVie
Phase 2
165
Cambridge, Edinburgh, London, Southampton, Norwich
2026-01-23
Recruiting
Efficacy and Safety of Vamifeport in Adult Participants With Homeostatic Iron Regulator Gene (HFE)-Related Hereditary Hemochromatosis
NCT07332091Homeostatic Iron Regulator Gene-related Hereditary Hemochromatosis
CSL Behring
Phase 2
84
Glasgow, Belfast, Bristol, Liverpool, London, Norwich, Nottingham, Oxford
2026-01-22
Recruiting
A Study to Investigate Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Acalabrutinib in Adults With Previously Untreated Chronic Lymphocytic Leukemia
NCT07277231Chronic Lymphocytic Leukemia
DrugsSonrotoclax·Acalabrutinib·Zanubrutinib·Venetoclax
BeOne Medicines
Phase 3
500
Birmingham, Bournemouth, Leeds, London, Norwich
2026-01-22
Recruiting
A Study to Compare Linvoseltamab Monotherapy and Linvoseltamab + Carfilzomib Combination Therapy With Standard-of-Care Combination Regimens in Adult Participants With Relapsed/Refractory Multiple Myeloma (RRMM)
NCT07222761Relapsed and/or Refractory Multiple Myeloma (RRMM)
DrugsLinvoseltamab·Carfilzomib·Bortezomib·Pomalidomide
Regeneron Pharmaceuticals
Phase 3
915
Aberdeen, Truro, Plymouth, Norwich, Birmingham, Dundee
2026-01-02
Recruiting
A Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Bevacizumab in Combination With Chemotherapy in Participants With Previously Untreated, Unresectable, or Metastatic Colorectal Cancer
NCT07221357Untreated, Unresectable, or Metastatic Colorectal Cancer
DrugsFolfiri·Capox·Folfox·Pumitamig
Bristol-Myers Squibb
Phase 2/3
990
Norwich, Manchester, Metropolitan Borough of Wirral, Oxford, Guildford, Birmingham, Cardiff, Dorchester
2025-12-31
Recruiting
Phase III Study of Datopotamab Deruxtecan Versus Docetaxel in Previously Treated TROP2-positive Advanced or Metastatic Non-squamous NSCLC Without Actionable Genomic Alterations
NCT07291037Non-small Cell Lung Cancer (NSCLC)
DrugsDatopotamab deruxtecan·Dato-DXd·Paclitaxel
AstraZeneca
Phase 3
400
Huddersfield, London, Maidstone, Norwich, Stoke-on-Trent
2025-10-31
Recruiting
A Phase 2 Trial to Investigate Efficacy and Safety of Vipoglanstat in Women With Endometriosis
NCT07260669Endometriosis
Gesynta Pharma AB
Phase 2
190
Bradford, Bristol, Corby, Coventry, London, Northwood, Norwich, Orpington
2025-10-15
Recruiting
An Induction Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Crohn's Disease
NCT07184931Crohn's Disease
DrugDuvakitug
Sanofi
Phase 3
980
Cottingham, Cambridge, London, Norwich, Rochdale
2025-10-01
Recruiting
A 52-week Study of Rilzabrutinib Efficacy and Safety Compared to Placebo in Adults Diagnosed With IgG4-related Disease
NCT07190196Immunoglobulin G4 Related Disease
DrugRilzabrutinib
Sanofi
Phase 3
124
London, Norwich, Oxford
2025-09-26
Recruiting
A Clinical Study of Tulisokibart (MK-7240) to Treat Radiographic Axial Spondyloarthritis (MK-7240-013)
NCT07133633Radiographic Axial Spondyloarthritis
DrugTulisokibart
Merck Sharp & Dohme LLC
Phase 2
315
Norwich, Bath, Barnet, Bradford
2025-09-26
Recruiting
A Study to Evaluate the Safety and Efficacy of Tacabrutideg (BGB-16673) Compared to Pirtobrutinib in Adults With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
NCT06973187Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
DrugsTacabrutideg·Pirtobrutinib
BeOne Medicines
Phase 3
500
Brighton, Canterbury, Norwich, Oxford, Roundhay, Salisbury
2025-09-04
Recruiting
A Study of Novel Agents or Combinations as Perioperative Treatment in Participants With Locally Advanced Resectable Gastroesophageal Adenocarcinoma
NCT07069712Gastroesophageal Adenocarcinoma
DrugsSonesitatug vedotin·Calcium folinate·Rilvegostomig·Leucovorin
AstraZeneca
Phase 2
100
Bristol, Dundee, Headington, London, Norwich
2025-07-17
Recruiting
A Study to Learn About the Study Medicine Called PF-07328948 in Adults With Heart Failure (BRANCH-HF)
NCT06991257Heart Failure
DrugPF-07328948
Pfizer
Phase 2
620
Dundee, London, Norwich, Chichester, Belfast, High Wycombe
2025-06-19
Recruiting
Phase III Study Investigating Heart Failure and Cardiovascular Death With Baxdrostat in Combination With Dapagliflozin
NCT06677060Heart Failure
AstraZeneca
Phase 3
11,300
Aberdeen, Chesterfield, Dundee, Gatley, Glasgow, London, Norwich, Penzance
2025-03-14
Recruiting
A Clinical Trial to Evaluate Efficacy and Safety of Navepegritide in Adolescents (12 - 18 Years of Age) With Achondroplasia.
NCT06732895Achondroplasia
DrugNavepegritide
Ascendis Pharma A/S
Phase 2
24
Norwich
2024-12-10
Recruiting
A Clinical Study of Molnupiravir to Prevent Severe Illness From Coronavirus Disease 2019 (COVID-19) in People Who Are High Risk (MK-4482-023)
NCT06667700Coronavirus Disease (COVID-19)
DrugMolnupiravir
Merck Sharp & Dohme LLC
Phase 3
3,082
Bristol, Exeter, Newcastle, Norwich, Northamptonshire, Bicester, Oxford, Somerset
2024-12-02
Recruiting
Surovatamig (AZD0486) as Monotherapy in Participants With Relapsed/Refractory (R/R) B-cell NHL
NCT06526793B-cell Non-Hodgkin Lymphoma, Follicular Lymphoma (FL), Large B-Cell Lymphoma (LBCL)
DrugSurovatamig
AstraZeneca
Phase 2
270
London, Manchester, Norwich, Nottingham, Plymouth
2024-11-27
Recruiting
Crohn's Disease: Efficacy, Safety, and Pharmacokinetics of Upadacitinib in Pediatric Subjects With Moderately to Severely Active Crohn's Disease
NCT06332534Crohn's Disease
DrugUpadacitinib
AbbVie
Phase 3
110
Cambridge, Sheffield, London, Norwich, Edinburgh
2024-08-08
Recruiting
A Study of Surovatamig (AZD0486) Plus Rituximab in Previously Untreated Follicular Lymphoma Patients
NCT06549595Untreated Follicular Lymphoma
DrugsSurovatamig·R-Chop
AstraZeneca
Phase 3
1,018
London, Newcastle upon Tyne, Norwich, Nottingham, Plymouth, Southampton
2024-08-07
Active, closed
A Study Comparing Pre- and Post-Change Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma
NCT06425991Multiple Myeloma
DrugTeclistamab
Janssen Research & Development, LLC
Phase 1
108
London, Manchester, Norwich, Plymouth
2024-06-07
Active, closed
INBRX-106 in Combination With Pembrolizumab in First-line PD-L1 CPSโ‰ฅ20 HNSCC
NCT06295731Head and Neck Squamous Cell Carcinoma (HNSCC)
DrugPembrolizumab
Inhibrx Biosciences, Inc
Phase 2/3
410
Chelsea, Northwood, Newcastle upon Tyne, Sutton, Aberdeen, Cambridge, Manchester, Norwich
2024-05-14
Recruiting
Phase III, Open-label, Study of First-line Dato-DXd in Combination With Rilvegostomig for Advanced Non-squamous NSCLC With High PD-L1 Expression (TC โ‰ฅ 50%) and Without Actionable Genomic Alterations
NCT06357533Non-Small Cell Lung Cancer
DrugsDatopotamab deruxtecan·Dato-DXd·Rilvegostomig·Pembrolizumab
AstraZeneca
Phase 3
675
Cheltenham, Inverness, London, Norwich, Preston, Truro
2024-04-11
Active, closed
An Open-label Extension Study of XTMAB-16 in Patients With Pulmonary Sarcoidosis
NCT06169397Pulmonary Sarcoidosis
Xentria, Inc.
Phase 2
31
Coventry, London, Norwich, Perth
2024-03-01
Active, closed
A Study of Acalabrutinib Plus Venetoclax and Rituximab in Participants With Treatment Naรฏve Mantle Cell Lymphoma
NCT05951959Mantle Cell Lymphoma (MCL)
DrugsAcalabrutinib·Venetoclax·Rituximab
AstraZeneca
Phase 2
108
Birmingham, Gloucester, London, Norwich, Nottingham, Plymouth
2023-12-13
Recruiting
A Trial to Learn if Odronextamab is Safe and Well-Tolerated and How Well it Works Compared to Rituximab Combined With Different Types of Chemotherapy for Adult Participants With Previously Untreated Follicular Lymphoma
NCT06091254Follicular Lymphoma (FL)
DrugsOdronextamab·Prednisone/Prednisolone·Bendamustine·Vincristine
Regeneron Pharmaceuticals
Phase 3
822
Truro, Plymouth, Bournemouth, Glasgow, Norwich, Romford
2023-12-12
Active, closed
MAXPIRe: Study to Evaluate Axatilimab in Participants With Idiopathic Pulmonary Fibrosis (IPF)
NCT06132256Idiopathic Pulmonary Fibrosis
DrugAxatilimab
Syndax Pharmaceuticals
Phase 2
145
Cambridge, Norwich, Oxford, Perth, Leeds, Birmingham
2023-12-11
Active, closed
Study of Tilpisertib Fosmecarbil in Participants With Moderately to Severely Active Ulcerative Colitis
NCT06029972Ulcerative Colitis
Gilead Sciences
Phase 2
176
Bury, Cambridge, London, Norwich, Southampton
2023-12-05
Active, closed
Study of Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Obinutuzumab in Participants With Chronic Lymphocytic Leukemia (CLL)
NCT06073821CLL
DrugsSonrotoclax·Zanubrutinib·Obinutuzumab·Venetoclax
BeOne Medicines
Phase 3
652
Bournemouth, Canterbury, Headington, Leeds, Liverpool, London, Norwich, Southampton
2023-11-11
Recruiting
A Study of XTMAB-16 in Patients With Pulmonary Sarcoidosis
NCT05890729Pulmonary Sarcoidosis
Xentria, Inc.
Phase 1/2
94
Coventry, London, Norwich, Oxford, Perth
2023-11-10
Recruiting
Liquid Biopsy System Intracoronary Blood Sampling and Analysis to Characterise Disease Biomarkers in Patients With Coronary Disease
NCT06259019Coronary Artery Disease
PlaqueTec Ltd
Not applicable
300
Bournemouth, Bristol, Cambridge, Norwich
2023-09-14
Active, closed
Prospective Observational Study of Effectiveness and Safety of Filgotinib in Participants With Ulcerative Colitis (UC)
NCT05817942Ulcerative Colitis
DrugFilgotinib
Alfasigma S.p.A.
Observational
509
Belfast, Bury, Exeter, Glasgow, London, Norwich, Oxford, Southampton
2023-06-12
Active, closed
Evaluation of the Safety and Efficacy of Eneboparatide (AZP-3601) in Patients With Chronic Hypoparathyroidism
NCT05778071Chronic Hypoparathyroidism, Endocrine System Diseases, Parathyroid Diseases
Alexion Pharmaceuticals, Inc.
Phase 3
165
Leicester, Norwich, Oxford
2023-06-07
Active, closed
A Study Evaluating the Effect of Filgotinib in Participants With Active Axial Spondyloarthritis
NCT05785611Axial Spondyloarthritis
DrugFilgotinib
Alfasigma S.p.A.
Phase 3
495
Bath, Norwich
2023-04-05
Recruiting
A Trial to Evaluate EP-104GI in Adults With Eosinophilic Esophagitis (EoE).
NCT05608681Eosinophilic Esophagitis
Eupraxia Pharmaceuticals Inc.
Phase 1/2
117
Norwich, Cardiff, Liverpool, London
2023-03-31
Active, closed
A Study Comparing Teclistamab Monotherapy Versus Pomalidomide, Bortezomib, Dexamethasone (PVd) or Carfilzomib, Dexamethasone (Kd) in Participants With Relapsed or Refractory Multiple Myeloma
NCT05572515Relapsed or Refractory Multiple Myeloma
DrugsTeclistamab·Carfilzomib·Bortezomib·Pomalidomide
Janssen Research & Development, LLC
Phase 3
614
Aberdeen, Birmingham, Colchester, Liverpool, London, Middlesbrough, Norwich, Staffordshire
2023-03-29
Active, closed
A Safety, Tolerability, and Immunogenicity Study of mRNA-1345 and mRNA-1365 in Participants Aged 5 Months to <24 Months
NCT05743881Respiratory Syncytial Virus, Human Metapneumovirus
DrugsMRNA-1345·MRNA-1365
ModernaTX, Inc.
Phase 1
186
Norwich
2023-02-15
Active, closed
A Study to Evaluate Change in Disease Activity of Subcutaneous (SC) Epcoritamab Combined With Intravenous and Oral Rituximab, Cyclophosphamide, Doxorubicin Hydrochloride, Vincristine, and Prednisone (R-CHOP) or R-CHOP in Adult Participants With Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL)
NCT05578976Diffuse Large B-Cell Lymphoma
DrugsEpcoritamab·Vincristine·Doxorubicin·Prednisone
Genmab
Phase 3
900
Birmingham, London, Norwich, Edinburgh
2023-02-08
Active, closed
Efficacy and Safety of Encaleret Compared to Standard of Care in Participants With ADH1
NCT05680818Autosomal Dominant Hypocalcemia (ADH)
DrugEncaleret
Calcilytix Therapeutics, Inc., a BridgeBio company
Phase 3
67
Newcastle upon Tyne, Norwich
2023-01-06
Recruiting
Post-Market Study to Assess iTind Safety in Comparison to UroLift
NCT04757116Benign Prostatic Hyperplasia (BPH)
Olympus Corporation of the Americas
Not applicable
256
Isleworth, Dunfermline, London, Norwich
2022-09-26
Active, closed
SC Versus IV Isatuximab in Combination With Pomalidomide and Dexamethasone in RRMM
NCT05405166Plasma Cell Myeloma Recurrent
DrugsMontelukast·Diphenhydramine·Isatuximab·Methylprednisolone
Sanofi
Phase 3
531
Derby, Birmingham, Leicester, London, Norwich
2022-06-23
Active, closed
Gekoโ„ข Cross Therapy Registry - Wound
NCT05007301Wound, Venous Leg Ulcer, Diabetic Foot Ulcer, Arterial Leg Ulcer
Firstkind Ltd
Observational
2,500
London, Norwich
2022-04-04
Recruiting
Study to Assess Change in Disease Activity and Adverse Events of Oral Venetoclax With Intravenous (IV) Obinutuzumab in Adult Participants With Recurring Chronic Lymphocytic Leukemia (CLL)
NCT04895436Chronic Lymphocytic Leukemia (CLL)
DrugsObinutuzumab·Venetoclax
AbbVie
Phase 2
75
Blackpool, Norwich, Leeds
2022-03-28
Active, closed
Effectiveness of the SpaceOAR Vue System in Subjects With Prostate Cancer
NCT04905069Prostate Cancer
Boston Scientific Corporation
Not applicable
500
Guildford, Cardiff, Belfast, Bristol, London, Norwich, Plymouth
2021-12-21
Recruiting
A Dose-Escalation and Expansion Study of Tacabrutideg (BGB-16673) in Participants With B-Cell Malignancies
NCT05006716B-cell Malignancy, Marginal Zone Lymphoma, Follicular Lymphoma, Non-Hodgkin Lymphoma
DrugTacabrutideg
BeOne Medicines
Phase 1/2
645
Edinburgh, Leeds, Newcastle upon Tyne, Newmarket, Norwich, Nottingham, Plymouth
2021-09-13
Active, closed
Study of LOXO-305 (Pirtobrutinib) Versus Investigator's Choice (Idelalisib Plus Rituximab or Bendamustine Plus Rituximab) in Patients With Previously Treated Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)
NCT04666038Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
DrugsTruxima·Idelalisib·Pirtobrutinib·Bendamustine
Loxo Oncology, Inc.
Phase 3
238
Aberdeen, Truro, Plymouth, Cottingham, London, Norwich, Swansea, Edinburgh
2021-03-09
Active, closed
Comparing UroLift Experience Against Rezลซm
NCT04338776Benign Prostatic Hyperplasia
NeoTract, Inc.
Not applicable
120
Frimley, Norwich, Cambridge
2021-01-22
Active, closed
A Phase 3 Trial of Epcoritamab vs Investigator's Choice Chemotherapy in Relapsed/Refractory (R/R) Diffuse Large B-cell Lymphoma (DLBCL)
NCT04628494Diffuse Large B-cell Lymphoma
DrugEpcoritamab
Genmab
Phase 3
483
Birmingham, London, Norwich, Nottingham, Plymouth, Southampton, Sutton, Truro
2021-01-13
Active, closed
A Clinical Efficacy and Safety Study of OHB-607 in Preventing Bronchopulmonary Dysplasia in Extremely Premature Infants
NCT03253263Bronchopulmonary Dysplasia, Chronic Lung Disease of Prematurity, Intraventricular Hemorrhage, Retinopathy of Prematurity (ROP)
OHB Neonatology Ltd.
Phase 2
295
Norwich, Chertsey, Cambridge, Coventry, Liverpool, London, Manchester
2019-05-09
Recruiting
Long-Term Real-World Outcomes Study on Patients Implanted With a Neurostimulator
NCT03876054Chronic Pain
Abbott Medical Devices
Observational
2,000
Norwich, Liverpool, Bristol, Leeds
2019-03-13
Active, closed
A Study Designed to Evaluate the Safety and Efficacy of Venetoclax Plus Dexamethasone (VenDex) Compared With Pomalidomide Plus Dexamethasone (PomDex) in Participants With t(11;14)-Positive Relapsed or Refractory Multiple Myeloma.
NCT03539744Multiple Myeloma
DrugsPomalidomide·Venetoclax·Dexamethasone
AbbVie
Phase 3
265
Cambridge, London, Norwich, Nottingham, Glasgow, Stoke-on-Trent, Manchester, Portsmouth
2018-10-22
Rows per page Showing 1–57 of 57
1
Cite this view

Priya Life Science (2026). Clinical trial register: industry-sponsored studies with a UK investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 25 September 2026. https://priyalifescience.com/clinical-trials-uk/city/norwich

Query this register directly
GET /api/trials?country=uk&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every industry-sponsored study on the registry that lists at least one investigative site in the UK and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 2,853 studies in total at the last sync on 25 Sep 2026, 03:15 UTC. Academic and other non-industry sponsors are out of scope by design. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 57 of those studies with a site in Norwich.

How many clinical trials are recruiting in Norwich?

35 of the 57 studies on this page are recruiting new participants as of the 25 Sep 2026, 03:15 UTC sync. A further 0 have not yet opened recruitment, 22 are active but closed to new participants, and 0 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Norwich), 57 studies
PhaseStudiesRecruitingShare
Phase 3261645.6%
Phase 214924.6%
Not applicable427%
Observational427%
Phase 1315.3%
Phase 1/2335.3%
Phase 2/3325.3%

Most active sponsors

Lead sponsors with the most studies (Norwich)
Lead sponsorStudiesRecruiting
AstraZeneca76
AbbVie43
BeOne Medicines43
Janssen Research & Development, LLC31
Sanofi32
Alfasigma S.p.A.20
Bristol-Myers Squibb22
Genmab20
Merck Sharp & Dohme LLC22
ModernaTX, Inc.21
Listing here is informational and not medical advice; eligibility is determined by each study team. Compare pay for the teams running these studies in the UK Pharma Salary Guide, or see the Ireland, EU and USA registers.